France Menopause Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Symptom, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
France · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$517.2 MnPlaceholder estimate
Estimate 2025$541.0 Mn2.9% of the global market
Projected 2034$811.0 Mn 49.9%Adds $269.9 Mn over 9 forecast years
CAGR 2025–20344.6%Faster than 19% of 180 Pharmaceuticals markets here
9 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The France Menopause Treatment Market Analysis Executive Summary
Menopause treatment relieves symptoms such as hot flashes, sleep problems and bone loss with hormone therapy, non-hormonal medicines and supplements.
Key segments of the menopause Treatment market include treatment (Hormone Replacement Therapy, Non-Hormonal Drugs and NK3 Receptor Antagonists) and symptom (Vasomotor Symptoms, Vaginal Atrophy and Osteoporosis).
France Menopause Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
France Menopause Treatment Market Dynamics
Market Growth Drivers
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the menopause Treatment market. New products designed around women's biology and digital care are improving access.
Opportunity
Femtech, personalised care and new treatments for under-served conditions open strong growth for the menopause Treatment market, especially as employers and payers add women's health benefits.
Market Restraints
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the menopause Treatment market.
Competitive Landscape for Menopause Treatment Market in France
The menopause Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Menopause Treatment Market in France
Menopause Treatment in France: rules, payment and research
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.[2] ClinicalTrials.gov lists 9 studies on Menopause Treatment that are recruiting, active or about to start in France.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for menopause Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Symptom
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Astellas Pharma
7.2 Bayer AG
7.3 Pfizer
7.4 Novo Nordisk
7.5 TherapeuticsMD
7.6 Mithra Pharmaceuticals
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The menopause Treatment market can be segmented based on various criteria, including treatment, symptom and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Menopause Treatment right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Menopause Treatment in context
France compared
Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
How big is the Menopause Treatment market in France?
Placeholder estimate: about $541.0 Mn in 2025, rising to about $811.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Menopause Treatment market in France growing?
Placeholder estimate: about 4.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Menopause Treatment market report cover?
The report splits the market by treatment (Hormone Replacement Therapy, Non-Hormonal Drugs, NK3 Receptor Antagonists, Supplements), symptom (Vasomotor Symptoms, Vaginal Atrophy, Osteoporosis, Sleep and Mood) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Menopause Treatment market?
Key players include Astellas Pharma Inc., Bayer AG, Pfizer Inc., Novo Nordisk A/S, TherapeuticsMD and Mithra Pharmaceuticals.
What is driving the Menopause Treatment market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the menopause Treatment market. New products designed around women's biology and digital care are improving access.
Who regulates Menopause Treatment in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on Menopause Treatment are running in France?
9 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
How much research is published on Menopause Treatment?
PubMed lists 28 papers on Menopause Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.